 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 November 1997 | Volume 127 Issue 10 | Pages 882-890
Background: Heterozygosity for a 32-nucleotide deletion in the C-C chemokine receptor 5 gene (CCR5 delta32) is associated with delayed disease progression in persons infected with HIV-1.
Objective: To compare the predictive value of CCR5 genotype with that of established markers in the clinical course of HIV-1 infection.
Design: Retrospective longitudinal study and nested case–control study. The latter included only long-term survivors, who were individually matched with progressors.
Setting: Amsterdam, the Netherlands.
Participants: 364 homosexual men with HIV-1 infection.
Measurements: Polymerase chain reaction was used for CCR5 genotyping. Univariate and multivariate Cox proportional-hazard analyses were done for disease progression with CCR5 genotype, CD4+ T-lymphocyte counts, T-lymphocyte function, HIV-1 biological phenotype (syncytium-inducing or non-syncytium-inducing HIV-1), and viral RNA load in serum as covariates.
Results: In the case–control study, 48% of long-term survivors were heterozygous for CCR5 delta32 compared with 9% of progressors (odds ratio, 6.9 [95% CI, 1.9 to 24.8]). In the total study sample, CCR5 delta32 heterozygotes had significantly delayed disease progression (P < 0.001; relative hazard, 0.4 [CI, 0.3 to 0.6]), a 1.5-fold slower decrease in CD4+ T-lymphocyte count (P = 0.01), and a 2.6-fold lower viral RNA load (P = 0.01) at approximately 2.3 years after seroconversion compared with CCR5 wild-type homozygotes. At the end of the study, both groups showed the same prevalence of syncytium-inducing HIV-1, but CCR5 delta32 heterozygotes had a delayed conversion rate. The protective effect of CCR5 delta32 heterozygosity was stronger in the presence of only non-syncytium-inducing HIV-1. The CCR5 genotype predicted disease progression independent of viral RNA load, CD4 T-lymphocyte counts, T-lymphocyte function, and HIV-1 biological phenotype.
Conclusions: The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection.
Author and Article Information
From the Central Laboratory of the Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam Academic Medical Center, and Municipal Health Service Amsterdam, Amsterdam, the Netherlands.
ARTICLE
Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection
Acknowledgments: The authors thank L. Berger, A. Holwerda, E. Hovenkamp, J. van de Hulst, and E. Poelstra for technical assistance and M.R. Klein and A.B. van 't Wout for critical reading of the manuscript.
Grant Support: By the Netherlands Foundation for Preventive Medicine grant 28-2547 within the Stimulation Program AIDS Research of the Dutch Programme Committee for AIDS Research (Programma Coordinatie Commissie AIDS Onderzoele, grant 95-026).
Requests for Reprints: Hanncke Schuitemaker, PhD, Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands.
Current Author Addresses: Drs. de Roda Husman, Koot, Miedema, and Schuitemaker. Ms. Brouwer, Ms. Broersen, and Ms. Roos: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, Department of Clinical Viro-Immunology, Plesmanlaan 125, 1066 CX Amsterdam, the Netherlands.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Levy Not an HIV Cure, but Encouraging New Directions N. Engl. J. Med., February 12, 2009; 360(7): 724 - 725. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Gulick, J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, J. Nadler, B. Clotet, A. Karlsson, M. Wohlfeiler, et al. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection N. Engl. J. Med., October 2, 2008; 359(14): 1429 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Quakkelaar, F. P. J. van Alphen, B. D. M. Boeser-Nunnink, A. C. van Nuenen, R. Pantophlet, and H. Schuitemaker Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies J. Virol., August 15, 2007; 81(16): 8533 - 8542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Jansen, I. M. De Cuyper, B. Hooibrink, A. K. van der Bij, D. van Baarle, and F. Miedema Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study Blood, February 15, 2006; 107(4): 1427 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Choudhary, N. R. Choudhary, K. C. Kimbrell, J. Colasanti, A. Ziogas, D. Kwa, H. Schuitemaker, and D. Camerini R5 Human Immunodeficiency Virus Type 1 Infection of Fetal Thymic Organ Culture Induces Cytokine and CCR5 Expression J. Virol., January 1, 2005; 79(1): 458 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. R. Kitchen, S. Philpott, H. Burger, B. Weiser, K. Anastos, and M. A. Suchard Evolution of Human Immunodeficiency Virus Type 1 Coreceptor Usage during Antiretroviral Therapy: a Bayesian Approach J. Virol., October 15, 2004; 78(20): 11296 - 11302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Beaumont, E. Quakkelaar, A. van Nuenen, R. Pantophlet, and H. Schuitemaker Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker J. Virol., June 1, 2004; 78(11): 5651 - 5657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Piriou, K. van Dort, N. M. Nanlohy, F. Miedema, M. H. van Oers, and D. van Baarle Altered EBV Viral Load Setpoint after HIV Seroconversion Is in Accordance with Lack of Predictive Value of EBV Load for the Occurrence of AIDS-Related Non-Hodgkin Lymphoma J. Immunol., June 1, 2004; 172(11): 6931 - 6937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chackerian, L. Briglio, P. S. Albert, D. R. Lowy, and J. T. Schiller Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus J. Virol., April 15, 2004; 78(8): 4037 - 4047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Campbell, K. Schneider, T. Wrin, C. J. Petropoulos, and E. Connick Relationship between In Vitro Human Immunodeficiency Virus Type 1 Replication Rate and Virus Load in Plasma J. Virol., November 15, 2003; 77(22): 12105 - 12112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. D. Thompson, E. G. Cormier, and T. Dragic CCR5 and CXCR4 Usage by Non-Clade B Human Immunodeficiency Virus Type 1 Primary Isolates J. Virol., February 22, 2002; 76(6): 3059 - 3064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P.A. Ioannidis, P. S. Rosenberg, J. J. Goedert, L. J. Ashton, T. L. Benfield, S. P. Buchbinder, R. A. Coutinho, J. Eugen-Olsen, T. Gallart, T. L. Katzenstein, et al. Effects of CCR5-{Delta} 32, CCR2-64I, and SDF-1 3'A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data Ann Intern Med, November 6, 2001; 135(9): 782 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Koning, D. Schols, and H. Schuitemaker No Selection for CCR5 Coreceptor Usage during Parenteral Transmission of Macrophagetropic Syncytium-Inducing Human Immunodeficiency Virus Type 1 J. Virol., September 15, 2001; 75(18): 8848 - 8853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dragic An overview of the determinants of CCR5 and CXCR4 co-receptor function J. Gen. Virol., August 1, 2001; 82(8): 1807 - 1814. [Full Text] [PDF]
|
|
|
|
|
|
D. Tamasauskas, V. Powell, K. Saksela, and K. Yazdanbakhsh A homologous naturally occurring mutation in Duffy and CCR5 leading to reduced receptor expression Blood, June 1, 2001; 97(11): 3651 - 3654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Hogan and S. M. Hammer Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics Ann Intern Med, May 15, 2001; 134(10): 978 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Trkola, T. J. Ketas, K. A. Nagashima, L. Zhao, T. Cilliers, L. Morris, J. P. Moore, P. J. Maddon, and W. C. Olson Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 J. Virol., January 15, 2001; 75(2): 579 - 588. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Shieh, Y.-E. Liau, P.-S. Hsieh, Y.-P. Yan, S.-T. Wang, and C. Li Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4 Int. Immunol., September 1, 2000; 12(9): 1311 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-X. Liao, D. C. Montefiori, D. D. Patel, D. M. Lee, W. K. Scott, M. Pericak-Vance, and B. F. Haynes Linkage of the CCR5{Delta}32 Mutation with a Functional Polymorphism of CD45RA J. Immunol., July 1, 2000; 165(1): 148 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. de Roda Husman, H. Blaak, M. Brouwer, and H. Schuitemaker CC Chemokine Receptor 5 Cell-Surface Expression in Relation to CC Chemokine Receptor 5 Genotype and the Clinical Course of HIV-1 Infection J. Immunol., October 15, 1999; 163(8): 4597 - 4603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garzino-Demo, R. B. Moss, J. B. Margolick, F. Cleghorn, A. Sill, W. A. Blattner, F. Cocchi, D. J. Carlo, A. L. DeVico, and R. C. Gallo Spontaneous and antigen-induced production of HIV-inhibitory beta -chemokines are associated with AIDS-free status PNAS, October 12, 1999; 96(21): 11986 - 11991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-H. Ping, J. A. E. Nelson, I. F. Hoffman, J. Schock, S. L. Lamers, M. Goodman, P. Vernazza, P. Kazembe, M. Maida, D. Zimba, et al. Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants J. Virol., August 1, 1999; 73(8): 6271 - 6281. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Dean, L. P. Jacobson, G. McFarlane, J. B. Margolick, F. J. Jenkins, O. M. Z. Howard, H.-F. Dong, J. J. Goedert, S. Buchbinder, E. Gomperts, et al. Reduced Risk of AIDS Lymphoma in Individuals Heterozygous for the CCR5-{{Delta}}32 Mutation Cancer Res., August 1, 1999; 59(15): 3561 - 3564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. van Baarle, E. Hovenkamp, M. J. Kersten, M. R. Klein, F. Miedema, and M. H.J. van Oers Direct Epstein-Barr Virus (EBV) Typing on Peripheral Blood Mononuclear Cells: No Association Between EBV Type 2 Infection or Superinfection and the Development of Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Blood, June 1, 1999; 93(11): 3949 - 3955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Michael, J. A. E. Nelson, V. N. KewalRamani, G. Chang, S. J. O'Brien, J. R. Mascola, B. Volsky, M. Louder, G. C. White II, D. R. Littman, et al. Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Delta 32 J. Virol., July 1, 1998; 72(7): 6040 - 6047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Rascoff and S. Blanche CCR5 Genotype and Mother-to-Child HIV Transmission JAMA, June 24, 1998; 279(24): 1953 - 1953. [Full Text] [PDF]
|
|
|
|
|
|
A. B. van 't Wout, H. Blaak, L. J. Ran, M. Brouwer, C. Kuiken, and H. Schuitemaker Evolution of Syncytium-Inducing and Non-Syncytium-Inducing Biological Virus Clones in Relation to Replication Kinetics during the Course of Human Immunodeficiency Virus Type 1 Infection J. Virol., June 1, 1998; 72(6): 5099 - 5107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Misrahi, J.-P. Teglas, N. N'Go, M. Burgard, M.-J. Mayaux, C. Rouzioux, J.-F. Delfraissy, S. Blanche, and for the French Pediatric HIV Infection Study Group CCR5 Chemokine Receptor Variant in HIV-1 Mother-to-Child Transmission and Disease Progression in Children JAMA, January 28, 1998; 279(4): 277 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pollakis, S. Kang, A. Kliphuis, M. I. M. Chalaby, J. Goudsmit, and W. A. Paxton N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization J. Biol. Chem., April 13, 2001; 276(16): 13433 - 13441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Migueles, M. S. Sabbaghian, W. L. Shupert, M. P. Bettinotti, F. M. Marincola, L. Martino, C. W. Hallahan, S. M. Selig, D. Schwartz, J. Sullivan, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors PNAS, March 14, 2000; 97(6): 2709 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cocchi, A. L. DeVico, R. Yarchoan, R. Redfield, F. Cleghorn, W. A. Blattner, A. Garzino-Demo, S. Colombini-Hatch, D. Margolis, and R. C. Gallo Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection PNAS, December 5, 2000; 97(25): 13812 - 13817. [Abstract] [Full Text] [PDF]
|
|
